Synthesis and biological evaluation of flavanones and flavones related to podophyllotoxin

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 1, 1998, Pages 79-83

  De Peredo, Anne Gonzalez ^a   Léonce, Stéphane ^b   Monneret, Claude ^a   Dauzonne, Daniel ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Cytotoxicity; Flavanone; Flavone; Podophyllotoxin analogue; Quinolone analogue

Indexed keywords

6 [3,5 DIMETHOXY 4 (PHENYLMETHOXY)PHENYL] 7 NITRO 8H 1,3 DIOXOLO [4,5 G][1]BENZOPYRAN 8 ONE; 7 CHLORO 6,7 DIHYDRO 7 NITRO 6 (3,4,5 TRIMETHOXYPHENYL) 8H 1,3 DIOXOLO[4,5 G][1]BENZOPYRAN 8 ONE; 7 NITRO 6 (3,4,5 TRIMETHOXYPHENYL) 8H 1,3 DIOXOLO[4,5 G][1]BENZOPYRAN 8 ONE; ANTINEOPLASTIC AGENT; DOXORUBICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG CONFORMATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 0345368009     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.79     Document Type: Article

References (62)

1. King L., Sullivan M., Science, 104, 244-245 (1946).
2. a) Stähelin H., Cerletti A., Schweiz. Med. Wschr., 94, 1490-1502 (1964);
3. b) Gensler W. J., Murthy C. D., Trammell M. H., J. Med. Chem., 20, 635-644 (1977);
4. c) Loike J. D., Brewer C. F., Sternlicht H., Gensler W. J., Horwitz S. B., Cancer Res., 38, 2688-2693 (1978);
5. d) Stähelin H., von Wartburg A., Prog. Drug. Res., 33, 169-266 (1989);
6. e) Jardine I., "Anticancer Agents Based on Natural Products Models," ed. by Cassady J. M., Douros J. D., Academic Press, New York, 1980, pp. 319-351;
7. f) Stähelin H. F., von Wartburg A., Cancer Res., 51, 5-15 (1991).
8. a) Falkson G., Sandison A. G., Vanzyl, J., S. Afr. J. Radiol., 2, 1-7 (1964);
9. b) Vaitkevicius V. K., Reed M. I., Cancer Chemother. Rep., 50, 565-571 (1966).
10. a) Stähelin H., Eur. J. Cancer, 6, 303-311 (1970);
11. b) Idem, ibid., 9, 215-221 (1973);
12. c) Cohen M. H., Broder L. E., Fossieck B. E., Ihde D. C., Minna J. D., Cancer Treat. Rep., 61, 489-490 (1977);
13. d) Aisner J., Wiernik P. H., Cancer, 46, 2543-2549 (1980);
14. e) Issell B. F., Cancer Chemother. Pharmacol., 7, 73-80 (1982);
15. f) Taylor R. E., Mc Elwain T. J., Barrett A., Peckham M. J., ibid., 7, 175-177 (1982);
16. g) Laubenstein L. J., Krigel R. L., Hymes K. B., Muggia F. M., Proc. Am. Soc. Clin. Oncol., 2, 228 (1983);
17. h) Issell B. F., Muggia F. M., Carter S. K., "[VP16] Current Status and New Developments," Academic Press, Orlando, 1984, pp. 1-353.
18. i) O'Dwyer P. J., Leyland-Jones B., Alonso M. T., Marsoni S., Wittes R. E., N. England J. Med., 312, 692-700 (1985);
19. j) Williams S. D., Birch R., Einhorn E. H., Irwin L., Greco F. A., Loehrer P. J., ibid., 316, 1435-1440 (1987);
20. k) Zhang Y., Lee K.-H., Chin. Pharm. J., 46, 319-369 (1994).
21. a) Cornman I., Cornman M. E., Ann. N. Y. Acad. Sci., 51, 1443-1487 (1951);
22. b) Kelly M. G., Hartwell J. L., J. Natl. Cancer Inst., 14, 967-1010 (1954);
23. c) Wilson L., Bryan J. Adv. Cell Mol. Biol., 3, 21-72 (1974);
24. d) Cortese F., Bhattacharyya B., Wolff J., J. Biol. Chem., 252, 1134-1140 (1977);
25. e) Andreu J. M., Timasheff S. N., Biochemistry, 21, 6465-6476 (1982);
26. f) Sackett D. L., Pharm. Ther., 59, 163-228 (1993).
27. a) Loike J. D., Horwitz S. B., Biochemistry, 15, 5435-5443 (1976);
28. b) Idem. ibid., 15, 5443-5448 (1976);
29. c) Grieder A., Maurer R., Stähelin H., Cancer Res., 37, 2998-3005 (1977);
30. d) Long B. H., Minocha A., Proc. Am. Assoc. Cancer Res., 24, 321 (1983);
31. e) Glisson B. S., Smallwood S. E., Ross W. E., Biochim. Biophys. Acta, 783, 74-79 (1984);
32. f) Minocha A., Long B. H., Biochem. Biophys. Res. Commun., 122, 165-170 (1984);
33. g) Liu E. F., Annu. Rev. Biochem., 58, 351-375 (1989);
34. h) MacDonald T. E., Lehnert E. K., Loper J. T., Chow K.-C., Ross W. E., "DNA Topoisomerases in Cancer," ed. by Potmesil M., Kohn K., W., Oxford University Press, New York, 1991, pp. 199-213;
35. i) Osheroff N., Robinson M. J., Zechiedrich E., ibid., pp. 230-239;
36. j) Wang, J. C., Annu. Rev. Biochem., 65, 635-692 (1996);
37. k) Burden D. A., Kingma P. S., Froelich-Ammon S. J., Bjornsti M.-A., Patchan M. W., Thompson R. B., Osheroff N., J. Biol. Chem., 271, 29238-29244 (1996);
38. Pommier Y., "Cancer Therapeutics: Experimental and Clinical Agents," ed. by Teicher B. A., Humana Press Inc., Totowa, New Jersey, 1997, pp. 153-174.
39. a) Li E., Wang H.-K., Kuo S.-C., Wu T.-S., Lednicer D., Lin C. M., Hamel E., Lee K.-H., J. Med. Chem., 37, 1126-1135 (1994);
40. b) Li E., Wang H.-K., Kuo S.-C., Wu T.-S., Mauger A., Lin C. M., Hamel E., Lee K.-H., ibid., 37, 3400-3407 (1994).
41. Wang H.-K., Bastow K. F., Cosentino L. M., Lee K.-H., J. Med. Chem., 39, 1975-1980 (1996).
42. a) Pathak D., Pathak K., Singla A. K., Fitoterapia, 62, 371-389 (1991);
43. b) Cody V., Middleton E., Harborne J. B. (eds.), "Progress in Clinical and Biological Research, Vol 213, Plant Flavonoids in Biology and Medicine," Alan R. Liss Inc., New York, 1986;
44. c) Cody V., Middleton E., Harborne J. B., Beretz A. (eds.), "Progress in Clinical and Biological Research, Vol 280, Plant Flavonoids in Biology and Medicine II," Alan R. Liss Inc., New York, 1988;
45. d) Cushman M., Nagarathnam D., J. Natl. Products, 54, 1656-1660 (1991);
46. e) Post J. F. M., Varma R. S., Cancer Lett., 67, 207-213 (1992);
47. f) Cunningham B. D. M., Threadgill M. D., Groundwater P. W., Dale I. L., Hickman J. A., Anti Cancer Drug Des., 7, 365-384 (1992);
48. g) Middleton E., Jr., Kandaswami C., "The Flavonoids, Advances in Research Since 1986," ed. by Harborne J. B., Chapman & Hall, London, 1993, pp. 619-652;
49. h) Sedlacek H. H., Czech J., Naik R., Kaur G., Worland P., Losiewicz M., Parker B., Carlson B., Smith A., Senderowicz A., Sausville E., Int. J. Oncol., 9, 1143-1168 (1996).
50. Dauzonne D., Demerseman P., Synthesis, 1990, 66-70.
51. Dauzonne D., Grandjean C., Synthesis, 1992, 677-680.
52. a) Kuivila H. G., Synthesis, 1970, 499-509;
53. b) Ono N., Kaji A., ibid. 1986, 693-704;
54. c) Neumann W. P., ibid., 1987, 665-683;
55. d) Rosini G., Ballini R., ibid., 1988, 833-847.
56. Fogh J., Trempe G., "Human Tumour Cells in Vitro," ed. by Fogh J., Plenum Press, New York, 1975, p. 119.
57. Fukui K., Nakayama M., Bull. Chem. Soc. Jpn., 35, 1321-1323 (1962).
58. Gross H., Rieche A., Matthey G., Chem. Ber., 96, 308-313 (1963).
59. Royer R., Buisson J.-P., Eur. J. Med. Chem.-Chim. Ther., 15, 275-278 (1980).
60. Particularly in the case of 9a, chromatography must be avoided because an important retro-reaction occurs on the column.
61. These moderate yields do not constitute an important drawback, since it is possible to recover unreacted salicylaldehyde 7 almost quantitatively (according to reference 10) and to recycle it.
62. Pierre A., Kraus-Berthier L., Atassi G., Cros S., Poupon M.-F., Lavielle G., Berlion M., Bizarri J.-P., Cancer Res., 51, 2312-2318 (1991).